KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic Results From a Phase 1 Single Ascending Dose Study
Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.118
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2019
Authors
Publisher
Elsevier BV